Onkologi DK’s Post

View organization page for Onkologi DK, graphic

568 followers

In this MEDtalk, Maria Bourlon presents the updated efficacy in the intention-to-treat population at 55-month median follow-up on the CheckMate 9ER phase 3 trial. The results show that the combination therapy with nivo+cabo continues to maintain meaningful long-term benefits in efficacy endpoints, such as progression-free survival, overall survival, and overall response rates. #Nyrecancer #Survival #Kidneycancer

Nivolumab + Cabozantinib Remains Standard of Care in First-Line Treatment for Advanced Renal Cell Carcinoma

Nivolumab + Cabozantinib Remains Standard of Care in First-Line Treatment for Advanced Renal Cell Carcinoma

https://bpno.dk

To view or add a comment, sign in

Explore topics